



A monthly report summarizing life science transactions in Washington State.

BY THE NUMBERS: (YTD) **40** TRANSACTIONS TOTALING OVER **\$2.23B**

Deals Per Sector



Disclosed Funding By Sector



MARCH TOP TRANSACTIONS

Rodeo Therapeutics Amgen Inc. and Rodeo Therapeutics announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues ([Amgen](#)).

Icosavax has raised \$100M to study viruslike particle vaccines against diseases including respiratory syncytial virus and COVID-19. The series B round equips Icosavax to take two assets into clinical trials this year ([FierceBiotech](#)).

OncoResponse raised a \$40.6M Series C investment round as it continues to develop antibodies that fight cancer. The company aims to harness antibodies from cancer patients who responded unusually well to immunotherapy treatments to make new treatments for patients whose systems do not respond well to existing options ([GeekWire](#)).

OTHER TRENDS & HIGHLIGHTS

Seattle's Life Science Cluster is the fifth strongest life science market in the country, according to a new report from JLL, led by world-renowned institutions and startups that have grown to become public companies. Seattle trails only Boston; the San Francisco Bay Area; Raleigh-Durham and San Diego ([GeekWire](#)).

Alexandria Real Estate An affidavit recorded with Snohomish County shows that Alexandria Real Estate Equities paid \$200M for Canyon Park Business Center. This is the second major Bothell acquisition in recent months for Alexandria, which develops office and lab space for life science companies ([Puget Sound Business Journal](#)).

Eliem Therapeutics raised \$60M in a Series B funding round to advance its pipeline of clinical and preclinical drugs. Eliem, founded in 2019, develops drugs to treat disorders like chronic pain, depression, epilepsy and anxiety ([Puget Sound Business Journal](#)).

*Eliem Therapeutics has major operations in Redmond but Pitchbook lists headquarters in UK and therefore does not appear as a listed transaction.

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
02-Mar-2021	Immusoft	Biotech	Later Stage VC	\$10,270,000	Seattle
02-Mar-2021	Presage Biosciences	Biotech	Later Stage VC	\$13,000,000	Seattle
03-Mar-2021	Inmedix	Medtech	Later Stage VC	\$2,000,000	Normandy Park
03-Mar-2021	Vesiflo	Medtech	Later Stage VC	\$90,000	Redmond
04-Mar-2021	GSL Solutions	Medtech	Merger/ Acquisition	undisclosed	Vancouver
10-Mar-2021	DexCare	Digital Health	Later Stage VC	\$20,000,000	Renton
10-Mar-2021	Innovega	Medtech	Equity Crowdfunding	undisclosed	Bellevue
12-Mar-2021	Impel NeuroPharma	Biotech	Later Stage VC	\$7,500,000	Seattle
12-Mar-2021	Modento	Digital Health	Merger/ Acquisition	undisclosed	Seattle
17-Mar-2021	AbSci	Biotech	Later Stage VC	\$125,000,000	Vancouver
18-Mar-2021	Curi Bio	Medtech	Later Stage VC	\$6,000,000	Seattle
19-Mar-2021	Icosavax	Biotech	Later Stage VC	\$99,730,000	Seattle
22-Mar-2021	Remmie	Medtech	Early Stage VC	\$10,000	Bothell
25-Mar-2021	OncoResponse	Biotech	Later Stage VC	\$40,630,000	Seattle
25-Mar-2021	Pathware	Medtech	Later Stage VC	\$35,000	Seattle
30-Mar-2021	Rodeo Therapeutics	Biotech	Merger/ Acquisition	\$721,000,000	Seattle
31-Mar-2021	Link Immunotherapeutics	Biotech	Seed Round	\$14,290,000	Seattle
31-Mar-2021	Outpace Bio	Biotech	Early Stage VC	\$30,000,000	Seattle
				March Total (disclosed transactions): \$1,089,960,000	
				February Total (disclosed transactions): \$666,580,000	
				January Total (disclosed transactions): \$478,070,000	